The tumor testing market encompasses the medical and diagnostic sector focused on identifying genetic mutations, biomarkers, and cellular alterations in solid and hematologic tumors. It includes technologies such as next-generation sequencing, polymerase chain reaction, and immunohistochemistry used for cancer screening, diagnosis, targeted therapy selection, and treatment monitoring across hospitals, diagnostic laboratories, and specialized cancer centers.
The global breast biopsy devices market was valued at USD 2,255.0 million in 2024 and reached USD 2,384.1 million in 2025, and it is projected to reach USD 3,261.7 million by 2030, growing at a compound annual growth rate (CAGR) of 6.5%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189011805
The tumor testing market is primarily driven by the rising global incidence of cancer, an increasing shift toward personalized medicine and targeted oncology therapies, and the growing adoption of next-generation sequencing (NGS) and liquid biopsy technologies. However, market growth is heavily restrained by the high cost of advanced molecular and genetic tests, unfavorable reimbursement scenarios in several regions, and a shortage of skilled molecular pathologists. Lucrative opportunities lie in expanding precision diagnostics into high-growth emerging markets, developing non-invasive multi-cancer early detection (MCED) assays, and integrating artificial intelligence into digital pathology and genomic interpretation. Despite these prospects, the market faces critical challenges, including complex regulatory clearance pathways for novel biomarkers, data privacy concerns, and persistent technical issues such as false positive or negative results and sample degradation during transport.
Target customers for the tumor testing market primarily comprise healthcare institutions—including public and private hospitals, dedicated cancer centers, pathology laboratories, and specialty oncology clinics—as well as biopharmaceutical companies and clinical research organizations (CROs). Institutional healthcare buyers prioritize high diagnostic accuracy, analytical sensitivity, procedural speed, regulatory compliance, and seamless integration with companion diagnostics to guide targeted therapy selection and longitudinal patient monitoring. Biopharmaceutical clients focus on robust genomic profiling, biomarker discovery, and patient stratification capabilities for clinical trials. Purchasing behavior among clinical buyers is heavily governed by reimbursement coverage, clinical utility evidence, and established institutional guidelines, favoring validated next-generation sequencing (NGS) panels, assay kits, and comprehensive profiling services through multi-year procurement contracts and direct sales channels.
Market entry, expansion, and profitability in the tumor testing market are heavily influenced by stringent regulatory frameworks, continuous technological advancements, and economic dynamics. Regulatory authorities such as the U.S. FDA enforce rigorous pre-market approvals, companion diagnostic clearances, and quality system standards for Next-Generation Sequencing (NGS) panels and liquid biopsy assays, which ensure clinical safety and analytical validity but can prolong deployment timelines and increase compliance costs. Technologically, the landscape is rapidly evolving with the integration of high-throughput sequencing platforms, non-invasive minimal residual disease (MRD) tracking, and artificial intelligence-driven digital pathology tools, requiring ongoing research and development investments to maintain competitive differentiation. Economically, while the rising global incidence of cancer and demand for personalized oncology drive strong overall market expansion, profitability remains sensitive to complex regional reimbursement structures, high initial capital expenditure for advanced diagnostic platforms, and pricing pressures imposed by institutional healthcare budgets.
The tumor testing and cancer profiling market is being significantly transformed by the rapid shift toward precision oncology, high-throughput next-generation sequencing (NGS), and non-invasive liquid biopsy platforms. Key emerging trends include the broad clinical adoption of comprehensive genomic profiling (CGP) over single-gene testing, enabling clinicians to evaluate complex biomarkers, actionable mutations, and novel targeted modalities simultaneously. Furthermore, minimal residual disease (MRD) monitoring, blood-based liquid biopsies, multi-cancer early detection, and the integration of artificial intelligence with digital pathology and electronic health records are streamlining diagnostic workflows and personalizing treatment plans. These trends are evolving rapidly, driven by accelerating double-digit market growth in segments like NGS and liquid biopsy, expanding regulatory clearances for companion diagnostics, and increasing investments in precision medicine across global healthcare systems.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189011805
Technological innovations disrupting the tumor testing market are centered on high-throughput genomic profiling, non-invasive diagnostics, and digital health integration. Key advancements gaining significant traction include next-generation sequencing (NGS) panels that allow for comprehensive genomic profiling of solid and hematologic tumors over single-gene assays. The industry is also witnessing rapid adoption of non-invasive liquid biopsy platforms and minimal residual disease (MRD) monitoring, which utilize blood-based circulating tumor DNA (ctDNA) to detect early recurrence without invasive tissue biopsies. Furthermore, the integration of artificial intelligence and machine learning with digital pathology and electronic health record systems is transforming cancer care by automating biomarker interpretation, improving diagnostic accuracy, and optimizing personalized, targeted therapy selection.
In the tumor testing market, short-term hype is primarily driven by temporary excitement around unvalidated direct-to-consumer testing kits, initial speculative buzz over early-stage single-biomarker claims, and marketing around unverified AI report generators. Conversely, long-term structural shifts are firmly anchored in the clinical adoption of precision oncology and routine molecular profiling. These permanent transformations include the widespread transition toward Next-Generation Sequencing (NGS) panels, the continuous shift from invasive tissue sampling to non-invasive liquid biopsies for minimal residual disease monitoring, and the deep integration of comprehensive genomic profiling data directly into electronic health record workflows to drive targeted therapy selection.
Source:https://www.marketsandmarkets.com/Market-Reports/biopsy-devices-breast-biopsy-market-189011805.html
